Your trusted destination for CME, CPD & Medical Education across the Middle East.
University of Milan, Fondazione IRCCS Policlinico Hospital, Italy
Prof. Maria Domenica Cappellini is a world-renowned authority in internal medicine, classical hematology, and rare red blood cell disorders, based at the University of Milan and the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. She completed her undergraduate medical degree (MD) with highest honors at the University of Milan, followed by comprehensive postgraduate residency training in internal medicine and hematology. Driven by a lifelong commitment to deciphering non-malignant hematologic diseases, she established her career at the forefront of global research into hemoglobinopathies, iron metabolism, and rare congenital anemias.
Practicing as Director of the Center for Rare Diseases and Senior Consultant Hematologist within the Department of Clinical Sciences and Community Health at the University of Milan, Prof. Cappellini has led one of Europe's top tertiary referral centers for severe hereditary blood disorders. Her specialized clinical scope encompasses beta-thalassemia major and intermedia, alpha-thalassemia, sickle cell anemia, iron overload organopathy, congenital dyserythropoietic anemias,rare porphyrias, and hereditary spherocytosis.
Throughout her distinguished career spanning over four decades, Prof. Cappellini has played a foundational role in defining the global standards for iron chelation therapy and iron monitoring. She has worked closely with international clinical trial networks, medical imaging specialists, and hepatologists to validate T2* magnetic resonance imaging (MRI) for tissue iron quantification in the liver and myocardium, transforming survival expectations and reducing cardiac mortality for transfusion-dependent patients worldwide.
A true pioneer in translational hematology, Prof. Cappellini has been instrumental in leading pivotal Phase II and Phase III global clinical trials for landmark therapeutic agents. Her seminal work led to the clinical approval and global adoption of luspatercept—a novel erythroid maturation agent—as well as novel oral iron chelators and gene-editing therapies (including CRISPR-Cas9 base-editing platforms) for patients with transfusion-dependent beta-thalassemia and severe sickle cell disease.
In addition to her clinical and research leadership, Prof. Cappellini is a passionate academic educator, mentor, and university administrator. She has trained hundreds of hematology fellows, internal medicine residents, and PhD candidates across Europe and internationally, directing university courses on clinical hematology, iron biology, and rare disease management. Her teaching philosophy emphasizes bridging basic molecular genetics with compassionate,comprehensive long-term clinical care for chronic hematologic conditions.
Prof. Cappellini is an extraordinarily prolific physician-scientist who has authored over 400 peer-reviewed scientific publications, chapters, and landmark consensus guidelines in leading high-impact medical journals, including The New England Journal of Medicine, The Lancet, Blood, Haematologica, and British Journal of Haematology. Her research portfolio focuses on characterizing ineffective erythropoiesis pathways, discovering novel modifiers of fetal hemoglobin (HbF) induction, and evaluating long-term organ toxicity in aging adult cohorts with hereditary anemias.
Beyond her institutional roles in Milan, Prof. Cappellini has served in key executive leadership positions across major global scientific organizations, including Past President of the European School of Haematology (ESH), Advisory Board Member for the European Hematology Association (EHA), and executive advisor to the Thalassemia International Federation (TIF). She regularly serves on WHO expert panels, international grant review committees, and editorial boards of top-tier hematology journals, helping shape national rare disease policies across Europe and the MENA region.
At the International Classical Hematology Conference 2026 (ICCH 2026), Prof. Maria Domenica Cappellini stands out as a core scientific pillar and keynote presenter. Translating molecular advances and landmark clinical trial data into practical management algorithms, she provides hematologists, internists, geneticists, and researchers across the globe with essential strategies to optimize hereditary anemia care, master iron chelation and erythroid maturation therapies, and advance precision medicine for patients worldwide.

MeetingMinds Experts
MeetingMinds Experts